Lupus erythematosus generally refers to systemic lupus erythematosus (SLE), and the life expectancy of SLE patients may be affected if they are not actively treated to control the disease.
SLE is a systemic connective tissue disease that can involve the skin and multiple organs. Patients with the disease produce a large number of autoantibodies that lead to immune disorders, causing damage to systems and tissues throughout the body. There is currently no effective cure for SLE, and as the disease progresses, it can lead to damage to organs such as kidneys, heart, lungs, etc., which can be life-threatening in severe cases.
The treatment of SLE is based on drug therapy (e.g. glucocorticosteroids such as prednisone, hydroxychloroquine, etc.), which can control the progression of the disease and minimize the recurrence of the disease after effective treatment. In recent years, the survival rate of SLE patients after treatment has been greatly improved. However, if patients are not actively treated to control the disease, their life expectancy may be affected.
SLE patients are advised to go to the rheumatology and immunology department of regular hospitals and other related departments for detailed consultation. The above medications should be used in accordance with the doctor’s prescription, and should not be used on their own.